Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 195

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 195
---
 |   |
| Issuance of ordinary shares from option exercise                            |     |                |      3 |   |     |                |      - |   |     |                    |      - |   |
| Issuance of ordinary shares                                                 |     |                |      - |   |     |                |      - |   |     |                    |  1,594 |   |
| Receipt (repayment) of an advance on account of shares                      |     |                |      - |   |     |                |      - |   |     |                    |   (200 | ) |
| NET CASH PROVIDED BY FINANCE ACTIVITIES                                     |     |                |      3 |   |     |                |      - |   |     |                    |  1,394 |   |
| INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS                            |     |                | (2,025 | ) |     |                |   (457 | ) |     |                    |    370 |   |
| CASH AND CASH EQUIVALENTS AT THE BEGINNING OF PERIOD                        |     |                |  5,293 |   |     |                |  1,186 |   |     |                    |    816 |   |
| CASH AND CASH EQUIVALENTS AT THE END OF PERIOD                              |     |                |  3,268 |   |     |                |    729 |   |     |                    |  1,186 |   |

<div align='center'>The accompanying notes are an integral part of
these financial statements.

F-7</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

NOTE 1:– GENERAL

On December
17, 2024, the Company completed the redomicile from the State of Delaware to the State of Nevada (the “Reincorporation. As a result
of the Reincorporation, the Company ceased its business existence as a Delaware corporation and continued its business existence as a
Nevada corporation under the name “Revium Rx.”

In November
2023, the Successor entered into a stock exchange agreement (“Share Exchange”) with Lipovation Ltd, a private Israeli company
engaged in the development of novel pharmaceutical solutions (“Lipovation” or the “Predecessor”). Following the closing
of